Corvel Corp CRVL
We take great care to ensure that the data presented and summarized in this overview for CORVEL CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRVL
View all-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA1.95MShares$656 Million1.46% of portfolio
-
Black Rock Inc. New York, NY1.47MShares$496 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.09MShares$366 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny654KShares$220 Million0.34% of portfolio
-
Dimensional Fund Advisors LP Austin, TX538KShares$181 Million0.04% of portfolio
-
State Street Corp Boston, MA360KShares$121 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY278KShares$93.5 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA254KShares$85.6 Million0.01% of portfolio
-
Boston Trust Walden Corp233KShares$78.4 Million0.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD210KShares$70.7 Million0.01% of portfolio
Latest Institutional Activity in CRVL
Top Purchases
Top Sells
About CRVL
CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.
Insider Transactions at CRVL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 05
2024
|
Mark E. Bertels EVP - Risk Management Services |
SELL
Open market or private sale
|
Direct |
350
-28.93%
|
$124,950
$357.35 P/Share
|
Dec 05
2024
|
Mark E. Bertels EVP - Risk Management Services |
BUY
Exercise of conversion of derivative security
|
Direct |
350
+22.44%
|
$18,200
$52.69 P/Share
|
Dec 02
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
6,000
-2.42%
|
$2,190,000
$365.05 P/Share
|
Nov 29
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
2,000
-0.8%
|
$734,000
$367.5 P/Share
|
Nov 26
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
2,000
-0.8%
|
$736,000
$368.0 P/Share
|
Nov 25
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
2,000
-0.79%
|
$750,000
$375.0 P/Share
|
Nov 22
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
7,200
-2.76%
|
$2,642,400
$367.31 P/Share
|
Nov 19
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
800
-0.31%
|
$289,600
$362.0 P/Share
|
Nov 12
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
2,000
-0.76%
|
$726,000
$363.08 P/Share
|
Nov 11
2024
|
Michael G Combs CEO & President |
SELL
Bona fide gift
|
Direct |
300
-1.08%
|
-
|
Nov 11
2024
|
Michael G Combs CEO & President |
SELL
Open market or private sale
|
Direct |
2,886
-17.14%
|
$1,041,846
$361.8 P/Share
|
Nov 11
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
2,000
-0.75%
|
$730,000
$365.0 P/Share
|
Nov 08
2024
|
V Gordon Clemons Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
1,000
-0.38%
|
$362,000
$362.31 P/Share
|
Nov 07
2024
|
Alan Hoops Director |
SELL
Open market or private sale
|
Indirect |
4,100
-8.69%
|
$1,414,500
$345.59 P/Share
|
Nov 07
2024
|
Alan Hoops Director |
SELL
Open market or private sale
|
Direct |
1,500
-15.96%
|
$517,500
$345.53 P/Share
|
Nov 06
2024
|
Brandon O'Brien Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
235
-1.74%
|
$82,250
$350.98 P/Share
|
Nov 06
2024
|
Brandon O'Brien Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+3.55%
|
$21,750
$87.69 P/Share
|
Sep 30
2024
|
Jennifer Yoss Vice President of Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
8
+1.15%
|
$2,480
$310.55 P/Share
|
Sep 30
2024
|
Brandon O'Brien Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8
+0.12%
|
$2,480
$310.55 P/Share
|
Sep 30
2024
|
Michael G Combs CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
10
+0.06%
|
$3,100
$310.55 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 69.7K shares |
---|---|
Other acquisition or disposition | 42K shares |
Bona fide gift | 4.92K shares |
Grant, award, or other acquisition | 59 shares |
Payment of exercise price or tax liability | 24.5K shares |
---|---|
Open market or private sale | 150K shares |
Bona fide gift | 91.2K shares |
Other acquisition or disposition | 42K shares |